|
|
免疫检查点抑制剂联合疗法在晚期非小细胞肺癌中的疗效研究进展
|
Abstract:
晚期非小细胞肺癌临床治疗选择有限且获益率低。如何延长生存期、提高生活质量及控制症状成为了当前研究的热点。免疫检查点抑制剂是治疗晚期非小细胞肺癌的重要手段，但患者临床治疗的应答率低。近年来，免疫检查点抑制剂联合疗法成为了抑制肿瘤发展的新策略。深入探究药物联用以及新兴免疫疗法的联合应用，或将成为提高肿瘤免疫疗效的关键策略之一，且对提高免疫检查点抑制剂临床治疗有效率及指导临床合理用药都具有重要的理论和实践价值。因此，本综述将总结常见免疫检查点抑制剂在晚期非小细胞肺癌中的疗效研究进展。
The clinical treatment options for advanced non-small cell lung cancer are limited and the success rate is low. The question of how to prolong survival, improve quality of life and control symptoms is the focus of current research. Immune checkpoint inhibitors (ICIs) are important for the treatment of advanced non-small cell lung cancer (NSCLC), but the response rate to clinical treatment is low. In recent years, combination therapy with ICIs has emerged as a new strategy to inhibit tumor development. The in-depth research of drug combinations and the combination of immunotherapies will become one of the key strategies to improve the efficacy of tumor immunity, and has important theoretical and practical value for improving the clinical efficacy of ICIs and for the rational use of clinical drugs. Therefore, this review summarizes the research progress of current ICIs in NSCLC.
| [1] | Leiter, A., Veluswamy, R.R. and Wisnivesky, J.P. (2023) The Global Burden of Lung Cancer: Current Status and Future Trends. Nature Reviews Clinical Oncology, 20, 624-639. https://doi.org/10.1038/s41571-023-00798-3 |
| [2] | Raskova Kafkova, L., Mierzwicka, J.M., Chakraborty, P., Jakubec, P., Fischer, O., Skarda, J., et al. (2024) NSCLC: From Tumorigenesis, Immune Checkpoint Misuse to Current and Future Targeted Therapy. Frontiers in Immunology, 15, Article 1342086. https://doi.org/10.3389/fimmu.2024.1342086 |
| [3] | Passaro, A., Jänne, P.A., Mok, T. and Peters, S. (2021) Overcoming Therapy Resistance in EGFR-Mutant Lung Cancer. Nature Cancer, 2, 377-391. https://doi.org/10.1038/s43018-021-00195-8 |
| [4] | Tagliamento, M., Genova, C., Rossi, G., Coco, S., Rijavec, E., Dal Bello, M.G., et al. (2019) Microtubule-Targeting Agents in the Treatment of Non-Small Cell Lung Cancer: Insights on New Combination Strategies and Investigational Compounds. Expert Opinion on Investigational Drugs, 28, 513-523. https://doi.org/10.1080/13543784.2019.1627326 |
| [5] | Guo, X., Chen, S., Wang, X. and Liu, X. (2023) Immune-Related Pulmonary Toxicities of Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Diagnosis, Mechanism, and Treatment Strategies. Frontiers in Immunology, 14, Article 1138483. https://doi.org/10.3389/fimmu.2023.1138483 |
| [6] | Ji, M., Liu, Y., Li, Q., Li, X., Zhao, W., Zhang, H., et al. (2015) PD-1/PD-L1 Pathway in Non-Small-Cell Lung Cancer and Its Relation with EGFR Mutation. Journal of Translational Medicine, 13, Article No. 5. https://doi.org/10.1186/s12967-014-0373-0 |
| [7] | Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., et al. (2019) Role of the Tumor Microenvironment in PD-L1/PD-1-Mediated Tumor Immune Escape. Molecular Cancer, 18, Article No. 10. https://doi.org/10.1186/s12943-018-0928-4 |
| [8] | Patel, S.A. and Weiss, J. (2020) Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy. Clinics in Chest Medicine, 41, 237-247. https://doi.org/10.1016/j.ccm.2020.02.010 |
| [9] | Nagel, T., Kalden, J.R. and Manger, B. (1998) Regulation der T-Zell-Aktivierung über CD28 und CTLA-4. Medizinische Klinik, 93, 592-597. https://doi.org/10.1007/bf03042674 |
| [10] | Leach, D.R., Krummel, M.F. and Allison, J.P. (1996) Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science, 271, 1734-1736. https://doi.org/10.1126/science.271.5256.1734 |
| [11] | Yang, J.C., Han, B., De La Mora Jiménez, E., Lee, J., Koralewski, P., Karadurmus, N., et al. (2024) Pembrolizumab with or without Lenvatinib for First-Line Metastatic NSCLC with Programmed Cell Death-Ligand 1 Tumor Proportion Score of at Least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. Journal of Thoracic Oncology, 19, 941-953. https://doi.org/10.1016/j.jtho.2023.12.023 |
| [12] | Herbst, R.S., Garon, E.B., Kim, D., Cho, B.C., Perez-Gracia, J.L., Han, J., et al. (2020) Long-Term Outcomes and Retreatment among Patients with Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology, 38, 1580-1590. https://doi.org/10.1200/jco.19.02446 |
| [13] | Nishio, M., Takahashi, T., Yoshioka, H., Nakagawa, K., Fukuhara, T., Yamada, K., et al. (2019) Keynote‐025: Phase 1b Study of Pembrolizumab in Japanese Patients with Previously Treated Programmed Death Ligand 1-Positive Advanced Non-Small‐Cell Lung Cancer. Cancer Science, 110, 1012-1020. https://doi.org/10.1111/cas.13932 |
| [14] | Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., et al. (2020) Updated Analysis from KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 1505-1517. https://doi.org/10.1200/jco.19.03136 |
| [15] | Garon, E.B., Aerts, J., Kim, J.S., Muehlenbein, C.E., Peterson, P., Rizzo, M.T., et al. (2021) Safety of Pemetrexed Plus Platinum in Combination with Pembrolizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Post Hoc Analysis of Keynote-189. Lung Cancer, 155, 53-60. https://doi.org/10.1016/j.lungcan.2021.02.021 |
| [16] | Xing, P., Wang, M., Zhao, J., Zhong, W., Chi, Y., Xu, Z., et al. (2021) Study Protocol: A Single‐Arm, Multicenter, Phase II Trial of Camrelizumab Plus Apatinib for Advanced Nonsquamous NSCLC Previously Treated with First‐Line Immunotherapy. Thoracic Cancer, 12, 2825-2828. https://doi.org/10.1111/1759-7714.14113 |
| [17] | Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S., Carcereny Costa, E., et al. (2019) Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 381, 2020-2031. https://doi.org/10.1056/nejmoa1910231 |
| [18] | Kelley, R.K., Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y., et al. (2021) Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients with Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 39, 2991-3001. https://doi.org/10.1200/jco.20.03555 |
| [19] | Sangro, B., Chan, S.L., Kelley, R.K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., et al. (2024) Four-Year Overall Survival Update from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Annals of Oncology, 35, 448-457. https://doi.org/10.1016/j.annonc.2024.02.005 |
| [20] | Lotze, M.T., Olejniczak, S.H. and Skokos, D. (2024) CD28 Co-Stimulation: Novel Insights and Applications in Cancer Immunotherapy. Nature Reviews Immunology, 24, 878-895. https://doi.org/10.1038/s41577-024-01061-1 |
| [21] | Kamphorst, A.O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D.L., et al. (2017) Rescue of Exhausted CD8 T Cells by PD-1-Targeted Therapies Is CD28-Dependent. Science, 355, 1423-1427. https://doi.org/10.1126/science.aaf0683 |
| [22] | Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., et al. (2024) Immune Checkpoint Inhibitors: Breakthroughs in Cancer Treatment. Cancer Biology & Medicin. https://doi.org/10.20892/j.issn.2095-3941.2024.0055 |
| [23] | Li, J., Huang, J., Jiang, Z., Li, R., Sun, A., Lai-Han Leung, E., et al. (2019) Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. Integrative Cancer Therapies, 18. https://doi.org/10.1177/1534735419890020 |
| [24] | Zhang, W., Li, S., Li, C., Li, T. and Huang, Y. (2022) Remodeling Tumor Microenvironment with Natural Products to Overcome Drug Resistance. Frontiers in Immunology, 13, Article 1051998. https://doi.org/10.3389/fimmu.2022.1051998 |
| [25] | Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. https://doi.org/10.1038/nature21349 |
| [26] | Huang, M., Jiang, X., Wang, B., Sun, Y. and Lu, J. (2021) Combination Therapy with PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer: Strategies and Mechanisms. Pharmacology & Therapeutics, 219, Article ID: 107694. https://doi.org/10.1016/j.pharmthera.2020.107694 |
| [27] | Butterfield, L.H. and Najjar, Y.G. (2023) Immunotherapy Combination Approaches: Mechanisms, Biomarkers and Clinical Observations. Nature Reviews Immunology, 24, 399-416. https://doi.org/10.1038/s41577-023-00973-8 |
| [28] | Sholl, L.M. (2022) Biomarkers of Response to Checkpoint Inhibitors Beyond PD-L1 in Lung Cancer. Modern Pathology, 35, 66-74. https://doi.org/10.1038/s41379-021-00932-5 |
| [29] | Lahiri, A., Maji, A., Potdar, P.D., Singh, N., Parikh, P., Bisht, B., et al. (2023) Lung Cancer Immunotherapy: Progress, Pitfalls, and Promises. Molecular Cancer, 22, Article No. 40. https://doi.org/10.1186/s12943-023-01740-y |
